Bionomics Limited

ABN 53 075 582 740

ASX ANNOUNCEMENT
10 February 2011

BNC105 Data Presented at Lorne Cancer Conference

10 February 2011; Adelaide, Australia: Bionomics Limited (ASX:BNO; ADR:BMICY) today announced that BNC105 would be the subject of three poster presentations at the 23rd Lorne Cancer Conference, Victoria Australia.

Thursday 10 February 2011:

> "Functional and molecular biomarker analysis demonstrates pharmacological activity for the novel vascular disrupting agent BNC105 in a first in human clinical study", to be presented by Dr David Bibby, Bionomics' Director Drug Development.

> "Discovery and clinical development of BNC105, a tubulin targeting small molecule that selectively disrupts the vasculature in solid tumours", to be presented by Dr Gabriel Kremmidiotis, Bionomics' Vice President Research and Development.

Friday 11 February 2011:

> "Evaluation of the anti-cancer effects of the tumour selective Vascular Disruptive Agent BNC105 in preclinical renal cancer models", to be presented by Dr Tina Lavranos, Head of Oncology Services, Neurofit.

The posters can be found on the Bionomics website www.bionomics.com.au

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited
Dr Deborah Rathjen
CEO & Managing Director
+618 8354 6101 / 0418 160 425
drathjen@bionomics.com.au

Monsoon Communications
Rudi Michelson
+613 9620 3333
rudim@monsoon.com.au

The Trout Group
Lauren Glaser
+1 646 378 2972
lglaser@troutgroup.com

About Bionomics Limited

Bionomics (ASX: BNO) is a leading international biotechnology company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, epilepsy and multiple sclerosis. BNC105, which is undergoing clinical development for the treatment of cancer, is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours. A clinical program is also underway for the treatment of anxiety disorders based on BNC210 which exhibits strong anxiolytic activity without side effects in preclinical models. Both compounds offer blockbuster potential if successfully developed.

Bionomics' discovery and development activities are driven by its three technology platforms: Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels). MultiCore® is Bionomics' proprietary, diversity orientated chemistry platform for the discovery of small molecule drugs. ionX® is a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system. These platforms underpin Bionomics' established business strategy and Bionomics is committed to securing partners for its key compounds.

For more information about Bionomics, visit www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of I995. Any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to the clinical evaluation of either BNCI05 or BNC2I0, our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.